

**Date: March 28, 2025**

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited (NSE),</b> Exchange Plaza, C – 1, Block – G, Bandra – Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, <b>BSE Limited,</b> 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001.
<b>Symbol-LINCOLN</b>	<b>Scrip Code-531633</b>

Dear Sir / Madam,

**Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).**

This is to inform that the National Stock Exchange of India Limited and BSE Limited have issued Cautionary Letters, both vide mail dated March 28, 2025 under the SEBI Listing Regulations, the details of which are provided in the Annexure.

As mentioned in the said letters, copies of same are being disseminated to the Stock Exchanges. We take note of the contents of the said letters and will adhere to the compliance(s) stated therein.

Thanking you,

Yours faithfully,

**For Lincoln Pharmaceuticals Ltd**

---

**Trusha Shah**  
**Company Secretary & Compliance Officer**  
**Encl.: As Above**

**Regd. Office :** "Lincoln House", B/h. Satyam Complex, Science City Road, Sola, Ahmedabad-380060, Gujarat, India.

**Phone :** +91-79-4107 8000 | **CIN** L24230GJ1995PLC024288

**E-mail :** info@lincolnpharma.com | **Website :** www.lincolnpharma.com

**Factory :** Trimul Estate, Khatraj, Tal.- Kalol, Dist.- Gandhinagar-382721, Gujarat State, India

**Phone :** +91-79-4913 5000 | **E-mail :** khatraj@lincolnpharma.com



**Annexure**

<b>SR No.</b>	<b>Particulars</b>	<b>Information/Remarks</b>
1.	Name of the authority	National Stock Exchange of India Limited (NSE) and BSE Limited (BSE)
2.	Nature and details of the action(s) taken, initiated or order(s) passed	Cautionary Letters issued by NSE and BSE, both dated March 28, 2025
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	March 28, 2025
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	Delay in submission of intimation of Schedule of Investors/ Analysts Meet
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on the financial, operation or other activities of the Company. We take note of the contents of the said letters and will adhere to the compliance(s) stated therein.

**Regd. Office :** "Lincoln House", B/h. Satyam Complex, Science City Road, Sola, Ahmedabad-380060, Gujarat, India.

**Phone :** +91-79-4107 8000 | **CIN** L24230GJ1995PLC024288

**E-mail :** info@lincolnpharma.com | **Website :** www.lincolnpharma.com

**Factory :** Trimul Estate, Khatraj, Tal.- Kalol, Dist.- Gandhinagar-382721, Gujarat State, India

**Phone :** +91-79-4913 5000 | **E-mail :** khatraj@lincolnpharma.com



## Trusha Shah

---

**From:** neaps@nse.co.in  
**Sent:** 28 March 2025 04:21 PM  
**To:** Trusha Shah  
**Subject:** LINCOLN - Cautionary Email

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on May 15, 2024 regarding the intimation of Schedule of Investors/ Analysts Meet/call to be held on May 16, 2024.

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI LODR ), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR. The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary email on the Stock Exchanges where they are listed.

Additionally, the Company is advised to place before their Board of Directors this Cautionary email and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

This is system generated email, you may reach out to the Announcements Team in case of any assistance at takeover@nse.co.in.

## Trusha Shah

---

**From:** Query lodr <query.lodr@bseindia.com>  
**Sent:** 28 March 2025 04:34 PM  
**To:** Trusha Shah  
**Subject:** Cautionary Letter

LIST/COMP/JP/1776/2024-25  
March 28, 2025

Date:

To,  
Company Secretary /Compliance Officer  
**Lincoln Pharmaceuticals Ltd (531633)**

### Sub: Cautionary letter

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on May 15, 2024, regarding the intimation of Schedule of Investors/ Analysts' Meet/ Call to be held on May 16, 2024

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet/call).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary Letter on the Stock Exchanges where they are listed. Additionally, the Company is advised to place before their Board of Directors this Cautionary Letter and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

Yours faithfully,

Listing Compliance Monitoring Team

**BSE Limited**

P J Towers, Dalal Street,

Mumbai - 400001, India

[www.bseindia.com](http://www.bseindia.com)

Tel: 022 2272 8561 / 8475

This mail is classified as '**CONFIDENTIAL**' by chetan.ag on March 28, 2025 at 16:33:29.

DISCLAIMER : The contents of this message may be legally privileged and confidential and are for the use of the intended recipient(s) only. It should not be read, copied and used by anyone other than the intended recipient(s). If you have received this message in error, please immediately notify the sender, preserve its confidentiality and delete it. Before opening any attachments please check them for viruses and defects. DISCLAIMER : The contents of

this message may be legally privileged and confidential and are for the use of the intended recipient(s) only. It should not be read, copied and used by anyone other than the intended recipient(s). If you have received this message in error, please immediately notify the sender, preserve its confidentiality and delete it. Before opening any attachments please check them for viruses and defects.